Precision medicine in cancer proposes that genomic characterization of tumors can inform personalized targeted therapies [1] [2] [3] [4] [5] . However, this proposition is complicated by spatial and temporal heterogeneity [6] [7] [8] [9] [10] [11] [12] [13] [14] . Here we study genomic and expression profiles across 127 multisector or longitudinal specimens from 52 individuals with glioblastoma (GBM). Using bulk and single-cell data, we find that samples from the same tumor mass share genomic and expression signatures, whereas geographically separated, multifocal tumors and/or long-term recurrent tumors are seeded from different clones. Chemical screening of patient-derived glioma cells (PDCs) shows that therapeutic response is associated with genetic similarity, and multifocal tumors that are enriched with PIK3CA mutations have a heterogeneous drug-response pattern. We show that targeting truncal events is more efficacious than targeting private events in reducing the tumor burden. In summary, this work demonstrates that evolutionary inference from integrated genomic analysis in multisector biopsies can inform targeted therapeutic interventions for patients with GBM.
Most clinical trials for targeted therapy in GBM have shown limited clinical success 15 . Although recent genome-wide studies evaluating regional heterogeneity 9, 11 and longitudinal GBM pairs 8, 12, 14, 16 have suggested potential evolutionary models of the tumors, there is little understanding regarding which strategies can effectively use genomic data to inform targeted therapies. To identify such strategies, we analyzed somatic variants in 127 multiregion or longitudinal tumor specimens from 52 individuals with glioma: 42 individuals from the Samsung Medical Center (SMC), Seoul, and 10 individuals from
The Cancer Genome Atlas (TCGA) GBM cohort 8, 14, 16 (Supplementary  Table 1 ). Additionally, we analyzed the transcriptomes of 83 tumor specimens from 41 individuals (bulk) and 305 single cells from 7 samples for 3 individuals. Tumors were classified into four distinct groups according to the spatial and temporal features of tissue acquisition: tumors obtained from the same location at the same time (locally adjacent), tumors obtained from different locations at the same time (multifocal/multicentric; referred to as multiple) 17 , and tumors obtained from local and distant recurrences at different times (longitudinal local and distant, respectively) (Fig. 1a) .
We inferred clonal and subclonal alterations from cancer cell fractions in multiple sectors (Online Methods and Supplementary Table 2 ). The average mutation rate was 2.2 mutations/Mb for nonhypermutated samples, which is consistent with previous studies 2, 14 . IDH1 mutations mapping to Arg132 were clonal across all of the regions in IDH-mutant tumors 2, 14 (6/6) . PIK3CA mutations were always clonal and shared by all sectors (5/5), which is consistent with the results of our previous longitudinal analysis from tumor evolution directed graphs (TEDGs), in which we found that PIK3CA mutations are early events 14 (Fig. 1b and Supplementary Fig. 1a,b) . Furthermore, FGFR3-TACC3 fusions were highly expressed in all regions from two individuals 18 . These somatic variants, which are shared by all tumor regions, represent promising therapeutic targets 14, 19 , as they reflect truncal alterations in the evolutionary tree that are suspected to be present among all tumor cells. In contrast, PTEN alterations, including copy number deletions and mutations, were shared by 10 of 20 (50%) and 5 of 7 (71.4%) tumor sectors, respectively. Likewise, EGFR amplifications were observed as private events, exclusive to only one or two regions of the multisector Spatiotemporal genomic architecture informs precision oncology in glioblastoma sample, in 4 of 15 (26.7%) of the EGFR-amplified tumors, including 2 multiple cases (GBM5 and GBM9). Furthermore, EGFR mutations were shared by 3 of 7 (42.9%) cases, including one harboring disjoint alterations, which are different genomic alterations in the same gene (GBM7-I1: p.Leu62Arg and p.Arg108Lys; GBM7-I2: p.Ala289Val and p.Cys624Ser), suggesting that partial genetic information from a single tumor biopsy can be inconclusive in assessing the potential benefit from EGFR-targeted therapy (Supplementary Fig. 1b,c) .
To understand the association between spatiotemporal architecture and genetic relevance, we calculated Nei's genetic distances among multisector samples from the same individual (Online Methods). Genetic diversity was greater in multiple tumors than in locally adjacent tissues (q = 4.7 × 10 −5 , Wilcoxon rank-sum test; Fig. 2a) , in distant recurrences than in local recurrences (q = 1.4 × 10 −5 , Wilcoxon rank-sum test; Fig. 2a) , and in long-term recurrence than in shortterm recurrences (q = 2.9 × 10 −3 , Wilcoxon rank-sum test; Fig. 2a) . Multinomial logistic regression was applied to classify multisector sample pairs on the basis of their genomic features (Supplementary Note). This analysis highlighted that tumors from distant regions or long-term recurrences, separated by surgical intervals exceeding 18 months, constitute a distinct evolutionary scenario in GBM (Fig. 2b) . In colorectal tumors, a Big Bang model 20 shows that cells from different biopsies of the same tumor share clonal and subclonal variants (Fig. 2c, left) . In accordance with this model, samples taken from locally adjacent tumors shared a large proportion of clonal and subclonal events (Supplementary Fig. 2a,b) . In contrast, multiple tumors contained fewer shared (more private) clonal mutations when compared to local tumors (q = 1.86 × 10 −3 , Wilcoxon rank-sum test; Supplementary Fig. 2a) . We corroborated this finding by computing statistics on the space of evolutionary trees (evolutionary moduli spaces; Online Methods and Supplementary Fig. 3 ). Locally adjacent tumors clustered near the tip of the space, indicating a higher shared mutation ratio than that of multiple tumors (P = 1.27 × 10 −2 , Wilcoxon rank-sum test). These results indicate that, in contrast to locally adjacent tumors, geographically separated multifocal tumors and/or long-term recurrent tumors are seeded from distinct clones, a phenomenon we call the 'multiverse model' (Fig. 2c, right) . Unlike the Big Bang model 20 , in the multiverse model, tumor samples that are derived from different tumor masses share very few genomic alterations, indicating that tumor clones are geographically segregated at an early stage of evolution and that each clone acquires distinct private alterations, leading to the construction of multiple universes. (b) Somatic mutations, including single-nucleotide variants (SNVs) and small insertions/deletions, copy number alterations, and gene fusions, for 83 glioma multiregion or multisector longitudinal specimens from 30 patients are shown. 34 locally adjacent tumor fragments from 14 patients, 13 multifocal/multicentric (referred to as multiple) tissues from 5 patients, and a longitudinal pair, GBM14, with leptomeningeal seeding were collected from the Samsung Medical Center (SMC). We also curated 34 multisector longitudinal tumor exomes and/or RNA sequencing data from 10 patients in The Cancer Genome Atlas (TCGA) cohort 8 . All somatic mutations called by SAVI with an allele frequency of >5% are shown. For each gene, we calculated copy number (CN) on the basis of Excavator results. Clonal alterations were determined using ABSOLUTE with a cancer cell fraction of >80% (Online Methods). CNV, copy number variation.
l e t t e r s l e t t e r s
Next, we investigated the mutation profiles of GBMs with multifocal/multicentric lesions (M-GBMs) or solitary lesions (S-GBMs) in a total of 160 treatment-naive individuals from both the SMC and TCGA 17 cohorts (Online Methods, Supplementary Figs. 4 and 5a, and Supplementary Table 3) . Notably, nonsynonymous mutations of PIK3CA were enriched in M-GBM (13/130 S-GBM and 9/30 M-GBM tumors; P = 7.905 × 10 −3 , Fisher's exact test; Fig. 2d ). This conclusion remained the same in the IDH1-wild-type cohort (Supplementary Fig. 5b ). PIK3CA induces multipotency of mammary tumors, suggesting that it has an associative role in tumor multiplicity 21 . Survival analysis indicated that both patients with M-GBM and PIK3CA-mutant patients had a worse prognosis than patients with S-GBM or wild-type PIK3CA (P = 0.0151 and 0.039, respectively, log-rank test; Supplementary Fig. 5c,d) .
To further characterize the heterogeneity of expression profiles, we curated single-cell RNA-seq data from a total of seven different samples from three patients. Overall, expression-based cell subtypes were not clearly determined by location or time (Fig. 3) , which is consistent with a previous report 10 . To make sure that this observation was not due to the limitations of this classification and to capture the transcriptional similarity among different cells, we used topological data analysis (Online Methods), a recently developed technique that summarizes and reduces the dimensionality of large data sets while retaining local high-dimensional structure 22, 23 . Fig. 3a-d ) consisted of samples from two initial tumors in the right and left frontal lobes and a recurrent tumor in the left frontal lobe that emerged after concurrent chemoradiotherapy (CCRT) and EGFR-targeted treatment (Supplementary Note). We found in bulk whole-exome sequencing (WES) and confirmed using ultradeep sequencing (Supplementary Table 4 ) and single-cell analysis that cells from the recurrent tumor shared genomic and expression features with initial tumor cells from the left frontal lobe (Fig. 3b and Supplementary Figs. 6-8) . Particularly, there were 61 somatic mutations shared by the left initial tumor and the recurrent tumor, while there were only 42 shared by the right initial tumor and the recurrent tumor. Single-cell transcriptome analysis showed EGFR expression predominantly in the right tumor mass, but not in the left initial and recurrent tumors (Fig. 3c) . Different single cells harbored different EGFR alterations, implying that these alterations were late events during tumor evolution 21 . PIK3CA mutations were detected from single cells in all three samples, which is consistent with the bulk WES result that PIK3CA mutations are founder events (Supplementary Figs. 1a  and 6a ). Our analysis also showed the presence of transcriptional heterogeneity within the individual samples. A subset of the left initial tumor cells was characterized by upregulation of mitotic genes that was not found in either the right or recurrent sections (Fig. 3d) .
GBM9 (
Additionally, we profiled IDH1-mutant tumor cells, which are distinguished by their 5-aminolevulinic acid (5-ALA) uptake l e t t e r s pattern (populations stained for tumor cellularity 24 ) (GBM10; Fig. 3e,f and Supplementary Figs. 6 and 7) . Previous glioma studies suggested that a low pathologic grade is associated with a low rate of 5-ALA uptake 24, 25 ; however, genomic determinants for 5-ALA uptake remain elusive. Using single-cell transcriptome analysis, we found predominant enrichment of proneural cells in the 5-ALA − sample, supporting previous observations that GBM cells may evolve from proneural precursors (P < 0.01, Fisher's exact test; Fig. 3e ) 26 . Also, we found enrichment of expression for several cell proliferation and migration markers in the 5-ALA + section, including MET and CD44 (refs. 27-29) . Notably, 5-ALA − tumors, which are considered to be less aggressive, are actually fully fledged tumors that harbor driver mutations and express markers for aggressive tumors (Fig. 3e,f and Supplementary Figs. 6b, 7, 9a , and 10). Finally, we studied main tumor and resection margin samples from GBM2-a locally adjacent hypermutated case-and found distinct subpopulations of cells expressing mitotic cell markers and migration-associated genes, including CD44 ( Fig. 3g and Supplementary Figs. 6, 7, 9 , and 10) 28 .
To investigate the influence of genetic heterogeneity on drug response, we isolated 28 PDCs from 11 individuals and screened 40 different cancer-related compounds (Supplementary Table 5 ) 4, 30 . We found that Nei's genetic distance was associated with drug-response correlation (P = 0.02, Wilcoxon rank-sum test; Fig. 4a) . Consistently, both distant and longitudinal samples showed significantly broader drug responses than local samples (Fig. 4b) . We found that the PDCs from M-GBMs were more sensitive to PI3K-AKT-mTOR (PAM) pathway inhibitors than PDCs from solitary tumors were (P = 1.872 × 10 −6 , Wilcoxon rank-sum test; Fig. 4c and Supplementary  Fig. 11 ). This indicates that PAM inhibitors could provide a clinical benefit for patients with M-GBM. In addition, we observed that PDCs from recurrent GBMs were more resistant to EGFR inhibitors than l e t t e r s the initial tumor cells were (P = 2.9 × 10 −4 , Wilcoxon rank-sum test; Supplementary Figs. 12 and 13) . We hypothesized that clonal alterations found in all multisector samples (truncal alterations) represent better molecular targets than those found in only a subset of multisector samples (private alterations). Video 1) , multisector PDCs were more sensitive to drugs that target shared alterations than to drugs that target private alterations (P = 0.0381, Wilcoxon rank-sum test; Online Methods, Fig. 4d and Supplementary Figs. 14-16 ). The multiverse model implies that the extensive genetic diversity of multiple tumors presents a special challenge. Accordingly, GBM9 showed a divergent genetic profile and a highly heterogeneous drug response (Fig. 4e,f) . PDCs from the rightside tumor were highly sensitive to EGFR inhibitors, but not to MEK inhibitors, and vice versa for the left-side tumor. However, inhibitors of the PAM pathway were ubiquitously effective, which is consistent with our hypothesis that targeting the PAM signaling pathway could be a potent option to treat M-GBMs (Fig. 4c,f) . Yet not all truncal alterations can serve as drug targets. For example, gatekeeper genes, which are necessary for tumor initiation but are no longer required for tumor maintenance, are not good candidates 31 . Although targeting subclonal mutations shows a limited effect, patients might still benefit from the elimination of a subclone that has a bystander effect on surrounding cells.
In agreement with this truncal-target hypothesis (Supplementary
In conclusion, on the basis of comprehensive bulk and single-cell analyses, we have proposed a multiverse model to interpret the evolution of multiple GBMs. We showed that M-GBMs are more genetically diverse than locally adjacent tumors and that genetic similarity between multiregion samples is associated with consistent drug response. Specifically, we found an enrichment of PIK3CA mutations in M-GBMs, and we found that inhibitors of the PAM pathway are more effective in PDCs from this cohort. These findings support the truncal-target hypothesis, which states that truncal mutations can inform more effective therapies. 
l e t t e r s oNLINe MetHoDs
Glioma specimens and their derivative cells. After receiving informed consents, glioma specimens and clinical records were obtained from patients undergoing surgery at Samsung Medical Center (SMC) or Seoul National University Hospital (SNUH) in accordance with its institutional review board (IRB file no. 2010-04-004). Surgical samples measuring approximately 5 × 5 × 5 mm 3 were snap-frozen using liquid nitrogen for genomic analysis. We also curated whole-exome and/or RNA sequencing of 33 multisector specimens from 10 glioblastoma (GBM) patients in The Cancer Genome Atlas (TCGA) cohort 8 and 22 previously reported GBM longitudinal pairs 14, 16 . To investigate the genomic characteristics of solitary and multifocal/multicentric GBMs, we curated exome sequencing data for 83 and 77 tumors with matched normal DNA from the SMC and TCGA cohorts 8, 17 , respectively. Portions of the surgical samples were enzymatically dissociated into single cells, following the procedures reported previously with modification of immune cell depletion 33 . Tumor cells were cultured in neurobasal medium with N2 and B27 supplements (0.5× each, half of the suggested working concentration; Invitrogen), human recombinant basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF; 20 ng/ml each; R&D Systems). The patient-derived cells (PDCs) used here had shown no obvious contamination of mycoplasma.
Radiological evaluation. Both T1-weighted contrast enhancement (T1CE) and fluid-attenuated inversion recovery (FLAIR)/T2 axial images of 160 treatment-naive GBMs (83 and 77 tumors from the SMC and TCGA cohorts, respectively) were reviewed. Magnetic resonance images (MRIs) of tumors from the TCGA cohort have been obtained from The Cancer Imaging Archive (TCIA) website 17, 34, 35 . We excluded cases with any evidence of prior neurosurgical intervention except biopsy, lack of treatment history, or loss of T1CE or FLAIR/T2 images. To distinguish the multifocal/multicentric GBMs (M-GBMs) from solitary ones (S-GBMs), we adapted annotations from the VASARI feature set for human glioma 36 . According to the VASARI feature set, m-GBMs are defined as having at least one region of tumor, either enhancing or nonenhancing, that is not contiguous with the main lesion and is outside of the region of signal abnormality (edema) surrounding the main mass 17, 37, 38 . When a FLAIR/T2 high-signal-intensity lesion resides outside of the T1CR lesion, it is considered a separate tumor focus and is counted as a multifocal tumor in our study 39, 40 . In contrast, tumors that present separate contrastenhancement lesions within the FLAIR/T2 high-signal-intensity background are considered as solitary ones.
Whole-exome sequencing. An Agilent SureSelect kit was used to capture the exonic DNA fragments. An Illumina HiSeq 2000 instrument was used for sequencing and generated 2 × 101-bp paired-end reads.
Somatic mutation. The sequenced reads in the FASTQ files were aligned to the human genome assembly (hg19) using Burrows-Wheeler aligner version 0.6.2. The initial alignment BAM files were subjected to conventional preprocessing before mutation calling: sorting, removing duplicated reads, locally realigning reads around potential small indels, and recalibrating base quality scores using SAMtools, Picard version 1.73, and Genome Analysis Toolkit (GATK) version 2.5.2. We used MuTect (version 1.1.4) and Somatic IndelDetector (GATK version 2.2) to make high-confidence predictions on somatic mutations from the neoplastic and non-neoplastic tissue pairs. Variant Effect Predictor (VEP) version 73 was used to annotate the called somatic mutations. Additionally, we ran SAVI (Statistical Variant Identification) software to call somatic variants and indels in order to for refine the mutation calls from the above pipeline.
Copy number. Excavator was used to generate estimated copy number alterations in a tumor specimen in comparison with its matching, non-neoplastic part. For each gene, we calculated copy number = 2 x +1 , where x is the segmentation mean from Excavator, which is defined as the log 2 (fold change) in the tumor divided by the normal sample. The gene was labeled as 'amplified' when the copy number was 3 and 'deleted' when it was ≤1.
Cancer cell fractions and clonality. We ran ABSOLUTE 41 using input of genomic variants and copy number data to infer sample purity and cancer cell fractions (CCFs) and removed those that had <20% purity. We considered mutations as clonal if they were indicated as clonal in ABSOLUTE and had a CCF of at least 80% or if they had a CCF of 100% and were not marked as clonal or subclonal. The ABSOLUTE CCF estimates with regard to hypermutated samples appeared disproportionately subclonal in sample GBM18 initial and in TCGA-14-1402 second recurrence; we reasoned that the large mutational load might skew estimates. In hypermutated samples, treatment-associated mutation coupled with defects in mismatch repair is deemed largely responsible for a majority of observed mutations. Therefore, mutations having CCFs greater than or equal to the maximum mismatch repair CCF were marked clonal in these two samples. If a mutation was found to be clonal in all sectors of a patient's tumor, it was inferred to be clonal throughout the entire tumor. We investigated the number of sequenced tumor sectors or cores needed to obtain a reasonable false discovery rate (FDR) for this inference of clonality. We analyzed glioma patient LGG174, published recently by Suzuki et al., where nine sectors from different locations of the same tumor mass were sequenced 42 . On the basis of Figure  7b from that paper 42 , 13 mutations have a high tumor cell fraction (>60%) shared by all samples. To relate the number of sectors that were sequenced to the number of mutations deemed to be clonal tumor-wide, we exhausted all possible subsampling strategies (number of cores k = 1, 2, …, 9) and calculated the reported clonal mutations based on k cores. For example, if there are two cores (k = 2), there are C 2 9 = 36 potential sampling strategies. We found that 22 of 36 sampling strategies contained no false discoveries in identifying clonal mutation. For each value of k, we calculated the FDR ( Supplementary  Fig. 17 ). Almost 90% of clonal mutations identified by two-core sequencing are true clonal mutations, and over 95% identified by three-core sequencing are true clonal mutations.
Nei's genetic distances. Nei's genetic distance is used in population genetics to assess the similarity between populations, taking into account heterogeneity within populations. Samples containing the same spatial or longitudinal category (local, 5-ALA, multiple lesion, longitudinal local, longitudinal distant) were retained for statistical comparisons. We calculated Nei's genetic distance of CCF for each patient's sample as follows. Let x be all CCFs of sample 1 and y be all CCFs of sample 2. The multiverse model of tumor evolution. We found an increased Nei's genetic distance in multifocal/multicentric biopsies when compared with those that were locally adjacent. In addition, private clonal mutations appear frequently in multisectional and distant longitudinal samples, but are infrequent in local samples (Supplementary Fig. 2a ). This spurred a hypothesis that specific early event(s) can give rise to distinct mutational profiles in spatially separated tumors (Fig. 2a) . These differences in mutational load suggested that distinct tumor profiles might arise in separate 'universes' of clones rather than from one large growth period followed by diversification.
For each somatic mutation, we recorded the clonal status as determined by ABSOLUTE and whether the mutation is shared or private, or the clonal status changed between biopsies. Mutations are then classified into five patterns with respect to every available pair of a patient's samples. The mutational classes were labeled as the following: CC (clonal-clonal), CS (clonal-subclonal), SS (subclonal-subclonal), CX (clonal-absent), or SX (subclonal-absent). The order of the sample pair was not important: a mutation that was clonal in one sample and subclonal in the other was marked "CS," regardless of sample identity.
These mutational classifications were used to predict whether the spatiotemporal configuration of a sample pair fell into one of three groups: locally adjacent, local longitudinal, or multisectional/distant longitudinal. The fractions of mutations in a sample pair that fit each of the five patterns were used as features in a multinomial logistic regression. Predictions were then made using leave-one-out cross-validation.
Mutational pairs plotted on the simplex allowed us to visually separate multisectional/distant longitudinal, locally adjacent, or local longitudinal sections in agreement with most of our MRI classifications. The simplex
